Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?

Hims & Hers shares plunged about 16% on Feb. 9 after the company abandoned plans to market a lower-cost copycat GLP-1 oral pill following an FDA declaration to restrict GLP-1 APIs in mass-marketed compounded drugs and a patent-infringement suit filed by Novo Nordisk. GLP-1 treatments have driven Hims & Hers' growth—revenue rose 74% year-over-year through the first nine months of 2025—but the FDA naming of Hims & Hers and ongoing litigation threaten a core revenue driver and have left the stock down over 58% in the past year, raising material legal and regulatory risk to future margins and market positioning.

Analysis

Market structure: Immediate winners are branded GLP-1 producers (Novo Nordisk NVO) and large-cap pharma with FDA-approved oral alternatives; direct losers are compounding-focused telehealth/specialty players (HIMS) and independent compounding pharmacies. Crackdown increases short-term pricing power for NVO by removing low-price substitutes, while forcing market share consolidation toward regulated supply over 3–12 months. Volatility will lift equity implied vol for small-cap health names (HIMS IV up >50% likely) and widen credit spreads for sub-investment grade healthcare borrowers.

Risk assessment: Tail risks include an FDA ban on compounding GLP-1 APIs or a successful preliminary injunction from Novo Nordisk that could erase >40–60% of HIMS’ GLP-1 revenue within 30–90 days; conversely, a court loss for NVO would re-open the low-cost substitute channel. Hidden dependency: HIMS’ growth (74% YTD) is concentrated in GLP-1s, implying >30–50% of near-term EBITDA at risk. Key catalysts in next 30–90 days: FDA final guidance, Novo Nordisk lawsuit filings, and payer formulary decisions.

Trade implications: Tactical short HIMS equity and buy protection via 3–6 month puts (establish ~3% notional short of portfolio; purchase 90-day ATM puts sized to 1–1.5% NAV) while layering a 6–12 month long NVO position (1–2% NAV) to capture pricing consolidation. Pair trade: short HIMS / long NVO to isolate regulatory risk (target entry HIMS down 15–30%, trim at 25–35% gains). Consider buying HIMS deep-OTM calls sized <0.5% NAV as asymmetric recovery optionality post-litigation resolution.

Contrarian angles: Consensus misses that FDA restriction could accelerate conversion to FDA-approved oral GLP-1s, lifting NVO revenue by +5–10% over 12 months versus base case; it also creates a multi-quarter rationing of cheap supply that benefits generics producers once patents expire. The sell-off in HIMS (−58% YTD) likely overprices permanent loss given potential pivot options (telehealth services, non-GLP therapeutics), making small, option-defined speculative longs reasonable after 30–60 days if legal filings favor HIMS or regulator signals soften.

Key Decisions for Investors

• Establish a 3% notional short position in HIMS (HIMS) funded size, and hedge with 3-month ATM puts sized to 1–1.5% NAV; target profit-taking at 25–35% move and stop-loss at 20% adverse move.
• Initiate a 1–2% NAV long position in Novo Nordisk (NVO) to capture pricing power if compounding channels close; add on FDA final guidance within 30–60 days or on a court ruling that favors branded enforcement.
• Execute a pair trade: short HIMS / long NVO in a 2:1 dollar ratio to isolate regulatory binary risk; rebalance after major catalysts (FDA guidance or preliminary injunction) within 30–90 days.
• Buy HIMS deep-OTM calls (<=0.5% NAV) with 6–12 month expiries as asymmetric, limited-loss exposure to an upside legal/regulatory outcome; only after 30–60 days of filings if implied vols decline >20%.
• Reduce small-cap telehealth exposure by 50% and rotate into large-cap pharma/defensive healthcare (NVO, large-cap generics) over the next 60–120 days to preserve cash for binary-event-driven opportunities.